SOLICITATION NOTICE
66 -- Basic Growth Factors
- Notice Date
- 8/16/2011
- Notice Type
- Presolicitation
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-110160-EB
- Archive Date
- 9/15/2011
- Point of Contact
- Erin M. Breedlove, Phone: 3014968607, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
breeerin@mail.nih.gov, cr214i@nih.gov
(breeerin@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Room 6074, Rockville, MD, 20852, UNITED STATES Description The National Cancer Institute (NCI), Center for Cancer Research (CCR), Neuro-Oncology Branch plans to procure on a sole source basis growth factors (recombinant human FCF, EGF and PDGF) from R&D Systems, Inc., 614 McKinley Place NE, Minneapolis, MN 55413-2647. The supplies herein are being procured in accordance with the simplified acquisition procedures as authorized by FAR Part 13.106-1 (b)(1). The North American Industry Classification System code is 325414 and the business size standard is 500 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Delivery date shall be September 15, 2011 or thirty days from time of award, whichever is later. The Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute is performing translational research on brain tumors, especially on the most malignant form - glioblastoma, using biological, biochemical, pathological, and immunological methods. The project utilizes neuronal/tumor stem cell cultures, and has been ongoing for more than seven years. The Neuro-Oncology Branch is employing unique cell culture methods to study gliomagenesis and the therapeutic strategies for brain tumors in which various growth factors, such as recombinant human FGF, EGF and PDGF are required. Three papers have been published in top journals in the cancer research field (Cancer Cell, 9:391-403, 2006; and 13:69-80, 2008; Cell Stem Cell, 4:440-452), and one is in press (J Natl Cancer Inst, 2011). The contractor shall provide: a) 20 1MG 37-18-FB-01M Recombinant Human FGF basic (145aa), CF b) 20 1MG 236-EG-01M Recombinant Human EGD, CF c) 5 50UG 220-BB-050 Recombinant Human PDGF-BB, CF R & D Systems is one of the leading life science and high technology companies to produce such specific cell culture supplements. The high quality stem cell culture supplements provided to the laboratory over the past several years has given the Neuro-Oncology Branch the best opportunity to study the role of neuronal stem cell in gliomagenesis and in the therapeutic strategies for gliomas. In this on-going project, the laboratory has used recombinant human FGF, EGF and PDGF from R & D Systems; changing the supplier of these products would introduce new variables into the on-going research and would be detrimental to the scientific validity of the results. Accordingly, R&D Systems is uniquely qualified to provide the growth factor supplements under this proposed procurement. This notice is not a request for a competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 11:00 AM EST, on August 31, 2011. For further information, please contact Erin Breedlove, Contract Specialist via electronic mail at Erin.Breedlove@nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed or emailed capability statements will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA). Reference: NCI-110160-EB on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-110160-EB/listing.html)
- Record
- SN02536105-W 20110818/110816235612-a6834588ef7ae4e93641e0fb0a43ba6a (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |